Loading...
Loading...
TLSI| Name | Value |
|---|---|
| Revenues | 5.2M |
| Cost of Revenue | 0.6M |
| Gross Profit | 4.6M |
| Operating Expense | 23.1M |
| Operating I/L | -18.5M |
| Other Income/Expense | 12.9M |
| Interest Income | 0.1M |
| Pretax | -1.3M |
| Income Tax Expense | -0.1M |
| Net Income/Loss | -1.3M |
TriSalus Life Sciences, Inc. is an immunotherapy company specializing in the development and commercialization of immunotherapies for liver and pancreatic tumors. The company's flagship products include the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology targeting various cancers such as hepatocellular carcinoma, uveal melanoma with liver metastases, and pancreatic ductal adenocarcinoma. These innovative treatments form the core of TriSalus' revenue stream, positioning the company as a key player in the field of immunotherapy for liver and pancreatic cancers.
